Organon & Co | OGN - Себестоимость





Себестоимость Изменить Дата
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Celltrion KRW 92.83B 14.59B 2026-03
Cspc Pharmaceutical CNY 2.11B 173.58M 2025-12
Deva Holding AS TRY 991.13M 182.81M 2023-09
Divis Laboratories Ltd INR 11.19B 1.2B 2026-06
Gilead Sciences USD 1000M 445M 2026-06
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Kangmei Pharma CNY 961.15M 119.7M 2026-06
Knight Therapeutics CAD 82.22M 1.03M 2025-12
Laboratorios Farma EUR 186.09M 11.06M 2023-12
Medical Developments International AUD 7.09M 4.91M 2025-12
Merck USD 3.14B 200M 2026-06
Neuren Pharmaceuticals AUD 7.45M 6.56M 2025-06
Novartis USD 3.46B 83M 2026-03
Organigram Holdings CAD 43.39M 13.54M 2026-03
Organon & Co USD 711M 34M 2026-06
Pharma Mar EUR 4.73M 1.08M 2026-06
Qiagen NV USD 196.45M 13.73M 2026-06
Sartorius EUR 478.7M 5.9M 2026-06
Sino Biopharmaceutical CNY 3.08B 589.65M 2025-06
Tilray USD 164.37M 8.41M 2025-09
Zealand Pharma A/S 410K 5K 2025-06